EUVIMEDEUVIMED entdecken
Crossref

FDA Revokes Approval for Preterm Birth Drug Makena

Emily Harris

JAMA · 2023

DOI: 10.1001/jama.2023.6257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: 17 alpha-Hydroxyprogesterone Caproate, Premature Birth, Drug Recalls, Reproductive Control Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

17 alpha-Hydroxyprogesterone CaproatePremature BirthDrug RecallsReproductive Control AgentsFemaleHumansInfant, NewbornDrug ApprovalUnited StatesUnited States Food and Drug Administration

Substanzen

17 alpha-Hydroxyprogesterone CaproateReproductive Control Agents

Zitieren

APA

Harris, E. (2023). FDA Revokes Approval for Preterm Birth Drug Makena. JAMA. https://doi.org/10.1001/jama.2023.6257

Vancouver

Harris E. FDA Revokes Approval for Preterm Birth Drug Makena. JAMA. 2023. doi:10.1001/jama.2023.6257

BibTeX
@article{Harris2023,
  author = {Harris, Emily},
  title = {FDA Revokes Approval for Preterm Birth Drug Makena},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.6257}
}
Kostenlos starten →